<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Randomized trials of surgery of the primary tumor in patients with de novo stage IV breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Randomized trials of surgery of the primary tumor in patients with de novo stage IV breast cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Randomized trials of surgery of the primary tumor in patients with de novo stage IV breast cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2"> </td> <td class="subtitle1" colspan="4">Trial</td> </tr> <tr> <td class="subtitle2">ECOG <span style="white-space: nowrap;">E2108<sup>[1]</sup></span></td> <td class="subtitle2"><span style="white-space: nowrap;">Austria<sup>[2,3]</sup></span></td> <td class="subtitle2"><span style="white-space: nowrap;">India<sup>[4]</sup></span></td> <td class="subtitle2"><span style="white-space: nowrap;">Turkey MF07-01<sup>[5]</sup></span></td> </tr> <tr> <td><strong>Accrual period</strong></td> <td>2011 to 2015</td> <td>2011 to 2015</td> <td>2005 to 2013</td> <td>2007 to 2012</td> </tr> <tr> <td><strong>Number of patients</strong></td> <td>256</td> <td>90</td> <td>350</td> <td>274</td> </tr> <tr> <td><strong>Inclusion</strong></td> <td>De novo stage IV breast cancer on systemic therapy for 4 to 8 months without progression</td> <td>Stage IV breast cancer</td> <td>De novo stage IV breast cancer with resectable hormone receptor-positive disease, <strong>or</strong> others with a partial or complete response to anthracycline-based chemotherapy</td> <td>De novo stage IV breast cancer</td> </tr> <tr> <td><strong>Prerandomization systemic therapy</strong></td> <td>Optimal systemic therapy × 4 to 8 months</td> <td>None</td> <td>6 to 8 cycles of anthracycline-based chemotherapy</td> <td>None</td> </tr> <tr> <td><strong>Stratification</strong></td> <td> <ul> <li>Hormone receptor status </li> <li>HER2 status </li> <li>Number of metastatic sites </li> <li>Endocrine therapy </li> <li>Chemotherapy </li> </ul> </td> <td> <ul> <li>Hormone receptor status </li> <li>HER2 status </li> <li>Grade </li> <li>Location of metastases </li> <li>Use of 1st-line chemotherapy </li> </ul> </td> <td> <ul> <li>Hormone receptor status </li> <li>Site of metastasis </li> <li>Number of metastatic lesions </li> </ul> </td> <td>None</td> </tr> <tr> <td><strong>Locoregional therapy in surgery group</strong></td> <td> <ul> <li>87% surgery (BCS + RT or mastectomy ± RT) </li> <li>AxD rate not reported </li> <li>80% clear margins </li> </ul> </td> <td> <ul> <li>71% mastectomy </li> <li>29% BCS + RT </li> <li>93% AxD </li> <li>76% clear margins </li> </ul> </td> <td> <ul> <li>72% mastectomy </li> <li>23% BCS + RT </li> <li>100% AxD </li> <li>Margin status not reported </li> </ul> </td> <td> <ul> <li>74% mastectomy </li> <li>26% BCS + RT </li> <li>93% AxD </li> <li>100% clear margins </li> </ul> </td> </tr> <tr> <td><strong>Median follow-up (months)</strong></td> <td>53</td> <td>37.5</td> <td>23</td> <td>40</td> </tr> <tr> <td><strong>OS (surgery versus no surgery)</strong></td> <td> <ul> <li>Median OS 54 months in both arms </li> <li>3-year OS 68 versus 68% </li> <li>HR 1.09, 90% CI 0.80-1.49; p = 0.63 </li> </ul> </td> <td> <ul> <li>Median OS 35 versus 55 months </li> <li>HR 0.69, 95% CI 0.36-1.33; p = 0.27 </li> </ul> </td> <td> <ul> <li>Median OS 19 versus 20.5 months </li> <li>2-year OS 42 versus 43% </li> <li>HR 1.04, 95% CI 0.81-1.34; p = 0.79 </li> </ul> </td> <td> <ul> <li>5-year OS 42 versus 24% </li> <li>HR 0.66, 95% CI 0.49-0.88; p = 0.005 </li> </ul> </td> </tr> <tr> <td><strong>LRP (surgery versus no surgery)</strong></td> <td>LRP 10 versus 26%, p = 0.003</td> <td>LRP 9 versus 18%, p = 0.22</td> <td>LRP-free survival: Median not attained versus 18.2 months; HR 0.16, 95% CI 0.10-0.26; p &lt;0.0001</td> <td>LRP 1 versus 11%, p = 0.001</td> </tr> <tr> <td><strong>Quality of life</strong></td> <td>Worse in surgery group at 18 months; no difference at 6 or 30 months</td> <td>No difference</td> <td>Not reported</td> <td>Not reported</td> </tr> </tbody></table></div><div class="graphic_footnotes">ECOG: Eastern Cooperative Oncology Group; HER2: human epidermal growth factor receptor 2; BCS: breast-conserving surgery; RT: radiation therapy; AxD: axillary dissection; OS: overall survival; HR: hazard ratio; CI: confidence interval; LRP: locoregional progression.</div><div class="graphic_reference">References: 

<ol>
<li>Khan SA, Zhao F, Solin LJ, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol 2020; 38S: ASCO #LBA2.</li>
<li>Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of breast surgery in primary metastasized breast cancer: Outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg 2019; 269:1163.</li>
<li>Bjelic-Radisic V, Fitzal F, Knauer M, et al. Primary surgery versus no surgery in synchronous metastatic breast cancer: Patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial. BMC Cancer 2020; 20:392.</li>
<li>Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial. Lancet Oncol 2015; 16:1380.</li>
<li>Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01. Ann Surg Oncol 2018; 25:3141.</li></ol></div><div id="graphicVersion">Graphic 130510 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
